Lyra Therapeutics

Update in progress

LYRA (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing anti-inflammatory therapies for chronic rhinosinusitis. Its approach delivers medicines directly to the affected tissue for sustained effect after a single administration. Lead candidate LYR-210 is an implantable anti-inflammatory drug matrix in Phase III for CRS; LYR-220 targets patients needing ongoing symptom control. The company collaborates with LianBio for several Asian markets and is based in Watertown, MA.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.33; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive